{
  "DOI": "10.1007/s00439-021-02282-3",
  "ISSN": [
    "0340-6717",
    "1432-1203"
  ],
  "URL": "http://dx.doi.org/10.1007/s00439-021-02282-3",
  "abstract": "\u003cjats:title\u003eAbstract\u003c/jats:title\u003e\u003cjats:p\u003ePharmaceutical companies have increasingly utilized genomic data for the selection of drug targets and the development of precision medicine approaches. Most major pharmaceutical companies routinely collect DNA from clinical trial participants and conduct pharmacogenomic (PGx) studies. However, the implementation of PGx studies during clinical development presents a number of challenges.  These challenges include adapting to a constantly changing global regulatory environment, challenges in study design and clinical implementation, and the increasing concerns over patient privacy. Advances in the field of genomics are also providing new opportunities for pharmaceutical companies, including the availability of large genomic databases linked to patient health information, the growing use of polygenic risk scores, and the direct sequencing of clinical trial participants. The Industry Pharmacogenomics Working Group (I-PWG) is an association of pharmaceutical companies actively working in the field of pharmacogenomics. This I-PWG perspective will provide an overview of the steps pharmaceutical companies are taking to address each of these challenges, and the approaches being taken to capitalize on emerging scientific opportunities.\u003c/jats:p\u003e",
  "alternative-id": [
    "2282"
  ],
  "assertion": [
    {
      "group": {
        "label": "Article History",
        "name": "ArticleHistory"
      },
      "label": "Received",
      "name": "received",
      "order": 1,
      "value": "22 February 2021"
    },
    {
      "group": {
        "label": "Article History",
        "name": "ArticleHistory"
      },
      "label": "Accepted",
      "name": "accepted",
      "order": 2,
      "value": "12 April 2021"
    },
    {
      "group": {
        "label": "Article History",
        "name": "ArticleHistory"
      },
      "label": "First Online",
      "name": "first_online",
      "order": 3,
      "value": "3 June 2021"
    },
    {
      "group": {
        "label": "Declarations",
        "name": "EthicsHeading"
      },
      "name": "Ethics",
      "order": 1
    },
    {
      "group": {
        "label": "Conflict of interest",
        "name": "EthicsHeading"
      },
      "name": "Ethics",
      "order": 2,
      "value": "Karina Bienfait Aparna Chhibber are an employees and stockholders of Bristol Myers Squibb. Jean-Claude Marshall is an employee and stockholder of Pfizer. Martin Armstrong is an employee and stockholder of UCB. Charles Cox is an employee and stockholder of GSK. Peter M. Shaw is an employee and stockholder of Merck \u0026 Co., and Charles Paulding is an employee and stockholder of Regeneron Pharmaceuticals."
    }
  ],
  "author": [
    {
      "affiliation": [],
      "family": "Bienfait",
      "given": "Karina",
      "sequence": "first"
    },
    {
      "affiliation": [],
      "family": "Chhibber",
      "given": "Aparna",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Marshall",
      "given": "Jean-Claude",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Armstrong",
      "given": "Martin",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Cox",
      "given": "Charles",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Shaw",
      "given": "Peter M.",
      "sequence": "additional"
    },
    {
      "ORCID": "http://orcid.org/0000-0002-7918-3561",
      "affiliation": [],
      "authenticated-orcid": false,
      "family": "Paulding",
      "given": "Charles",
      "sequence": "additional"
    }
  ],
  "container-title": [
    "Human Genetics"
  ],
  "content-domain": {
    "crossmark-restriction": false,
    "domain": [
      "link.springer.com"
    ]
  },
  "created": {
    "date-parts": [
      [
        2021,
        6,
        3
      ]
    ],
    "date-time": "2021-06-03T14:03:52Z",
    "timestamp": 1622729032000
  },
  "deposited": {
    "date-parts": [
      [
        2022,
        6,
        9
      ]
    ],
    "date-time": "2022-06-09T02:07:43Z",
    "timestamp": 1654740463000
  },
  "indexed": {
    "date-parts": [
      [
        2024,
        3,
        26
      ]
    ],
    "date-time": "2024-03-26T18:47:03Z",
    "timestamp": 1711478823886
  },
  "is-referenced-by-count": 12,
  "issn-type": [
    {
      "type": "print",
      "value": "0340-6717"
    },
    {
      "type": "electronic",
      "value": "1432-1203"
    }
  ],
  "issue": "6",
  "issued": {
    "date-parts": [
      [
        2021,
        6,
        3
      ]
    ]
  },
  "journal-issue": {
    "issue": "6",
    "published-print": {
      "date-parts": [
        [
          2022,
          6
        ]
      ]
    }
  },
  "language": "en",
  "license": [
    {
      "URL": "https://creativecommons.org/licenses/by/4.0",
      "content-version": "tdm",
      "delay-in-days": 0,
      "start": {
        "date-parts": [
          [
            2021,
            6,
            3
          ]
        ],
        "date-time": "2021-06-03T00:00:00Z",
        "timestamp": 1622678400000
      }
    },
    {
      "URL": "https://creativecommons.org/licenses/by/4.0",
      "content-version": "vor",
      "delay-in-days": 0,
      "start": {
        "date-parts": [
          [
            2021,
            6,
            3
          ]
        ],
        "date-time": "2021-06-03T00:00:00Z",
        "timestamp": 1622678400000
      }
    }
  ],
  "link": [
    {
      "URL": "https://link.springer.com/content/pdf/10.1007/s00439-021-02282-3.pdf",
      "content-type": "application/pdf",
      "content-version": "vor",
      "intended-application": "text-mining"
    },
    {
      "URL": "https://link.springer.com/article/10.1007/s00439-021-02282-3/fulltext.html",
      "content-type": "text/html",
      "content-version": "vor",
      "intended-application": "text-mining"
    },
    {
      "URL": "https://link.springer.com/content/pdf/10.1007/s00439-021-02282-3.pdf",
      "content-type": "application/pdf",
      "content-version": "vor",
      "intended-application": "similarity-checking"
    }
  ],
  "member": "297",
  "page": "1165-1173",
  "prefix": "10.1007",
  "published": {
    "date-parts": [
      [
        2021,
        6,
        3
      ]
    ]
  },
  "published-online": {
    "date-parts": [
      [
        2021,
        6,
        3
      ]
    ]
  },
  "published-print": {
    "date-parts": [
      [
        2022,
        6
      ]
    ]
  },
  "publisher": "Springer Science and Business Media LLC",
  "reference": [
    {
      "DOI": "10.1161/CIRCULATIONAHA.107.737312",
      "author": "JL Anderson",
      "doi-asserted-by": "publisher",
      "first-page": "2563",
      "journal-title": "Circulation",
      "key": "2282_CR1",
      "unstructured": "Anderson JL, Horne BD, Stevens SM, Grove AS, Barton S, Nicholas ZP, Kahn SF, May HT, Samuelson KM, Muhlestein JB, Carlquist JF, Couma-Gen I (2007) Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation 116:2563–2570. https://doi.org/10.1161/CIRCULATIONAHA.107.737312",
      "volume": "116",
      "year": "2007"
    },
    {
      "key": "2282_CR2",
      "unstructured": "Argentina (2000) http://www.jus.gob.ar/media/3201023/personal_data_protection_act25326.pdf. Accessed 8 Mar 2021"
    },
    {
      "DOI": "10.1007/978-1-59745-439-1_7",
      "doi-asserted-by": "crossref",
      "key": "2282_CR3",
      "unstructured": "Armstrong M (2008) The genetics of adverse drug reactions. In: Pharmacogenomics and personalized medicine. Springer"
    },
    {
      "DOI": "10.1002/cpt.762",
      "author": "PCD Bank",
      "doi-asserted-by": "publisher",
      "first-page": "599",
      "journal-title": "Clin Pharmacol Ther",
      "key": "2282_CR4",
      "unstructured": "Bank PCD, Caudle KE, Swen JJ, Gammal RS, Whirl-Carrillo M, Klein TE, Relling MV, Guchelaar HJ (2018) Comparison of the guidelines of the clinical pharmacogenetics implementation consortium and the dutch pharmacogenetics working group. Clin Pharmacol Ther 103:599–618. https://doi.org/10.1002/cpt.762",
      "volume": "103",
      "year": "2018"
    },
    {
      "DOI": "10.2174/1389201018666170103103619",
      "author": "E Cecchin",
      "doi-asserted-by": "publisher",
      "first-page": "204",
      "journal-title": "Curr Pharm Biotechnol",
      "key": "2282_CR5",
      "unstructured": "Cecchin E, Roncato R, Guchelaar HJ, Toffoli G, Ubiquitous Pharmacogenomics C (2017) Ubiquitous pharmacogenomics (U-PGx): the time for implementation is now. An horizon 2020 program to drive pharmacogenomics into clinical practice. Curr Pharm Biotechnol 18:204–209. https://doi.org/10.2174/1389201018666170103103619",
      "volume": "18",
      "year": "2017"
    },
    {
      "DOI": "10.1002/cpt.1664",
      "author": "MJ Chenoweth",
      "doi-asserted-by": "publisher",
      "first-page": "57",
      "journal-title": "Clin Pharmacol Ther",
      "key": "2282_CR6",
      "unstructured": "Chenoweth MJ, Giacomini KM, Pirmohamed M, Hill SL, van Schaik RHN, Schwab M, Shuldiner AR, Relling MV, Tyndale RF (2020) Global pharmacogenomics within precision medicine: challenges and opportunities. Clin Pharmacol Ther 107:57–61. https://doi.org/10.1002/cpt.1664",
      "volume": "107",
      "year": "2020"
    },
    {
      "DOI": "10.1056/NEJMoa1907096",
      "author": "DMF Claassens",
      "doi-asserted-by": "publisher",
      "first-page": "1621",
      "journal-title": "N Engl J Med",
      "key": "2282_CR7",
      "unstructured": "Claassens DMF, Vos GJA, Bergmeijer TO, Hermanides RS, Van’ t Hof AWJ, van der Harst P, Barbato E, Morisco C, Tjon Joe Gin RM, Asselbergs FW, Mosterd A, Herrman JR, Dewilde WJM, Janssen PWA, Kelder JC, Postma MJ, de Boer A, Boersma C, Deneer VHM, Ten Berg JM (2019) A genotype-guided strategy for oral P2Y12 inhibitors in primary PCI. N Engl J Med 381:1621–1631. https://doi.org/10.1056/NEJMoa1907096",
      "volume": "381",
      "year": "2019"
    },
    {
      "key": "2282_CR8",
      "unstructured": "CLIA (2003) https://www.govinfo.gov/content/pkg/USCODE-2011-title42/pdf/USCODE-2011-title42-chap6A-subchapII-partF-subpart2-sec263a.pdf. Accessed 8 Mar 2021"
    },
    {
      "DOI": "10.1056/NEJMoa054013",
      "author": "JC Cohen",
      "doi-asserted-by": "publisher",
      "first-page": "1264",
      "journal-title": "N Engl J Med",
      "key": "2282_CR9",
      "unstructured": "Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH (2006) Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 354:1264–1272. https://doi.org/10.1056/NEJMoa054013",
      "volume": "354",
      "year": "2006"
    },
    {
      "DOI": "10.1161/CIRCULATIONAHA.119.044434",
      "author": "A Damask",
      "doi-asserted-by": "publisher",
      "first-page": "624",
      "journal-title": "Circulation",
      "key": "2282_CR10",
      "unstructured": "Damask A, Steg PG, Schwartz GG, Szarek M, Hagstrom E, Badimon L, Chapman MJ, Boileau C, Tsimikas S, Ginsberg HN, Banerjee P, Manvelian G, Pordy R, Hess S, Overton JD, Lotta LA, Yancopoulos GD, Abecasis GR, Baras A, Paulding C, Regeneron Genetics C, the OOI, (2020) Patients with high genome-wide polygenic risk scores for coronary artery disease may receive greater clinical benefit from alirocumab treatment in the ODYSSEY OUTCOMES Trial. Circulation 141:624–636. https://doi.org/10.1161/CIRCULATIONAHA.119.044434",
      "volume": "141",
      "year": "2020"
    },
    {
      "DOI": "10.1097/01.fpc.0000054116.14659.e5",
      "author": "AA Desai",
      "doi-asserted-by": "publisher",
      "first-page": "517",
      "journal-title": "Pharmacogenetics",
      "key": "2282_CR11",
      "unstructured": "Desai AA, Innocenti F, Ratain MJ (2003) UGT pharmacogenomics: implications for cancer risk and cancer therapeutics. Pharmacogenetics 13:517–523. https://doi.org/10.1097/01.fpc.0000054116.14659.e5",
      "volume": "13",
      "year": "2003"
    },
    {
      "DOI": "10.1126/science.aaf6814",
      "author": "FE Dewey",
      "doi-asserted-by": "publisher",
      "journal-title": "Science",
      "key": "2282_CR12",
      "unstructured": "Dewey FE, Murray MF, Overton JD, Habegger L, Leader JB, Fetterolf SN, O’Dushlaine C, Van Hout CV, Staples J, Gonzaga-Jauregui C, Metpally R, Pendergrass SA, Giovanni MA, Kirchner HL, Balasubramanian S, Abul-Husn NS, Hartzel DN, Lavage DR, Kost KA, Packer JS, Lopez AE, Penn J, Mukherjee S, Gosalia N, Kanagaraj M, Li AH, Mitnaul LJ, Adams LJ, Person TN, Praveen K, Marcketta A, Lebo MS, Austin-Tse CA, Mason-Suares HM, Bruse S, Mellis S, Phillips R, Stahl N, Murphy A, Economides A, Skelding KA, Still CD, Elmore JR, Borecki IB, Yancopoulos GD, Davis FD, Faucett WA, Gottesman O, Ritchie MD, Shuldiner AR, Reid JG, Ledbetter DH, Baras A, Carey DJ (2016) Distribution and clinical impact of functional variants in 50,726 whole-exome sequences from the DiscovEHR study. Science. https://doi.org/10.1126/science.aaf6814",
      "year": "2016"
    },
    {
      "DOI": "10.1038/s41467-018-06540-3",
      "author": "D Diogo",
      "doi-asserted-by": "publisher",
      "first-page": "4285",
      "journal-title": "Nat Commun",
      "key": "2282_CR13",
      "unstructured": "Diogo D, Tian C, Franklin CS, Alanne-Kinnunen M, March M, Spencer CCA, Vangjeli C, Weale ME, Mattsson H, Kilpelainen E, Sleiman PMA, Reilly DF, McElwee J, Maranville JC, Chatterjee AK, Bhandari A, Nguyen KH, Estrada K, Reeve MP, Hutz J, Bing N, John S, MacArthur DG, Salomaa V, Ripatti S, Hakonarson H, Daly MJ, Palotie A, Hinds DA, Donnelly P, Fox CS, Day-Williams AG, Plenge RM, Runz H (2018) Phenome-wide association studies across large population cohorts support drug target validation. Nat Commun 9:4285. https://doi.org/10.1038/s41467-018-06540-3",
      "volume": "9",
      "year": "2018"
    },
    {
      "DOI": "10.17226/25094",
      "doi-asserted-by": "publisher",
      "key": "2282_CR14",
      "unstructured": "Downey AS, Busta ER, Mancher M, Botkin JR (2018) Returning Individual Research Results to Participants: Guidance for a New Research Paradigm. In: Downey AS, Busta ER, Mancher M, Botkin JR (eds) National Academies of Sciences, Engineering, and Medicine; Health and Medicine Division; Board on Health Sciences Policy; Committee on the Return of Individual-Specific Research Results Generated in Research Laboratories. National Academies Press (US), Washington (DC). https://doi.org/10.17226/25094"
    },
    {
      "DOI": "10.1146/annurev-pharmtox-010814-124835",
      "author": "HM Dunnenberger",
      "doi-asserted-by": "publisher",
      "first-page": "89",
      "journal-title": "Annu Rev Pharmacol Toxicol",
      "key": "2282_CR15",
      "unstructured": "Dunnenberger HM, Crews KR, Hoffman JM, Caudle KE, Broeckel U, Howard SC, Hunkler RJ, Klein TE, Evans WE, Relling MV (2015) Preemptive clinical pharmacogenetics implementation: current programs in five US medical centers. Annu Rev Pharmacol Toxicol 55:89–106. https://doi.org/10.1146/annurev-pharmtox-010814-124835",
      "volume": "55",
      "year": "2015"
    },
    {
      "key": "2282_CR16",
      "unstructured": "EMA (2018) Good pharmacogenomic practice."
    },
    {
      "author": "FDA",
      "key": "2282_CR17",
      "unstructured": "FDA (2013) Guidance for industry clinical pharmacogenomics: premarket evaluation in early-phase clinical studies and recommendations for labeling. US Department of Health and Human Services, Silver Spring",
      "volume-title": "Guidance for industry clinical pharmacogenomics: premarket evaluation in early-phase clinical studies and recommendations for labeling",
      "year": "2013"
    },
    {
      "key": "2282_CR18",
      "unstructured": "FDA (2015) Table of pharmacogenomic biomarkers in drug labeling. https://www.fda.gov/drugs/science-and-research-drugs/table-pharmacogenomic-biomarkers-drug-labeling. Accessed 8 Mar 2021"
    },
    {
      "key": "2282_CR19",
      "unstructured": "FDA (2017) 2015–2016 global participation in clinical trials report."
    },
    {
      "key": "2282_CR20",
      "unstructured": "FDA (2019) Enrichment strategies for clinical trials to support determination of effectiveness of human drugs and biological products guidance for industry."
    },
    {
      "key": "2282_CR21",
      "unstructured": "GDPR (2016) General Data Protection Regulation (GDPR). https://gdpr-info.eu."
    },
    {
      "DOI": "10.1038/sj.tpj.6500171",
      "author": "C Guillemette",
      "doi-asserted-by": "publisher",
      "first-page": "136",
      "journal-title": "Pharmacogenomics J",
      "key": "2282_CR22",
      "unstructured": "Guillemette C (2003) Pharmacogenomics of human UDP-glucuronosyltransferase enzymes. Pharmacogenomics J 3:136–158. https://doi.org/10.1038/sj.tpj.6500171",
      "volume": "3",
      "year": "2003"
    },
    {
      "DOI": "10.2217/pgs-2019-0022",
      "author": "Z Guo",
      "doi-asserted-by": "publisher",
      "first-page": "631",
      "journal-title": "Pharmacogenomics",
      "key": "2282_CR23",
      "unstructured": "Guo Z, Caro L, Robertson MN, Hwang P, Hoover P, Wudarski C, Maiuri K, Wang YH, Mogg R, Mehrotra DV, Blanchard R, Shaw PM (2019) The pharmacogenetics of OATP1B1 variants and their impact on the pharmacokinetics and efficacy of elbasvir/grazoprevir. Pharmacogenomics 20:631–641. https://doi.org/10.2217/pgs-2019-0022",
      "volume": "20",
      "year": "2019"
    },
    {
      "DOI": "10.1161/CIRCULATIONAHA.119.041546",
      "author": "JC Hopewell",
      "doi-asserted-by": "publisher",
      "journal-title": "Circulation",
      "key": "2282_CR24",
      "unstructured": "Hopewell JC, Ibrahim M, Hill M, Shaw PM, Braunwald E, Blaustein RO, Bowman L, Landray MJ, Sabatine MS, Collins R (2019) Impact of ADCY9 genotype on response to anacetrapib. Circulation. https://doi.org/10.1161/CIRCULATIONAHA.119.041546",
      "year": "2019"
    },
    {
      "key": "2282_CR25",
      "unstructured": "IDPA (2014) https://www.garanteprivacy.it/home/docweb/-/docweb-display/docweb/3786078."
    },
    {
      "DOI": "10.1007/s40264-020-00915-6",
      "author": "RN Jerome",
      "doi-asserted-by": "publisher",
      "first-page": "567",
      "journal-title": "Drug Saf",
      "key": "2282_CR26",
      "unstructured": "Jerome RN, Joly MM, Kennedy N, Shirey-Rice JK, Roden DM, Bernard GR, Holroyd KJ, Denny JC, Pulley JM (2020) Leveraging human genetics to identify safety signals prior to drug marketing approval and clinical use. Drug Saf 43:567–582. https://doi.org/10.1007/s40264-020-00915-6",
      "volume": "43",
      "year": "2020"
    },
    {
      "DOI": "10.1073/pnas.1922867117",
      "author": "Z Khan",
      "doi-asserted-by": "publisher",
      "first-page": "12288",
      "journal-title": "Proc Natl Acad Sci USA",
      "key": "2282_CR27",
      "unstructured": "Khan Z, Di Nucci F, Kwan A, Hammer C, Mariathasan S, Rouilly V, Carroll J, Fontes M, Ley Acosta S, Guardino E, Chen-Harris H, Bhangale T, Mellman I, Rosenberg J, Powles T, Hunkapiller J, Chandler GS, Albert ML (2020) Polygenic risk for skin autoimmunity impacts immune checkpoint blockade in bladder cancer. Proc Natl Acad Sci USA 117:12288–12294. https://doi.org/10.1073/pnas.1922867117",
      "volume": "117",
      "year": "2020"
    },
    {
      "DOI": "10.1038/s41588-018-0183-z",
      "author": "AV Khera",
      "doi-asserted-by": "publisher",
      "first-page": "1219",
      "journal-title": "Nat Genet",
      "key": "2282_CR28",
      "unstructured": "Khera AV, Chaffin M, Aragam KG, Haas ME, Roselli C, Choi SH, Natarajan P, Lander ES, Lubitz SA, Ellinor PT, Kathiresan S (2018) Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations. Nat Genet 50:1219–1224. https://doi.org/10.1038/s41588-018-0183-z",
      "volume": "50",
      "year": "2018"
    },
    {
      "DOI": "10.1016/j.xphs.2017.04.051",
      "author": "ME Klein",
      "doi-asserted-by": "publisher",
      "first-page": "2368",
      "journal-title": "J Pharm Sci",
      "key": "2282_CR29",
      "unstructured": "Klein ME, Parvez MM, Shin JG (2017) Clinical implementation of pharmacogenomics for personalized precision medicine: barriers and solutions. J Pharm Sci 106:2368–2379. https://doi.org/10.1016/j.xphs.2017.04.051",
      "volume": "106",
      "year": "2017"
    },
    {
      "DOI": "10.1002/jcph.1420",
      "author": "J Kobie",
      "doi-asserted-by": "publisher",
      "first-page": "1236",
      "journal-title": "J Clin Pharmacol",
      "key": "2282_CR30",
      "unstructured": "Kobie J, Guo Z, Cho CR, Menzel K, McCrea JB, Blanchard R, Shaw PM (2019) Pharmacogenetic analysis of OATP1B1, UGT1A1, and BCRP variants in relation to the pharmacokinetics of letermovir in previously conducted clinical studies. J Clin Pharmacol 59:1236–1243. https://doi.org/10.1002/jcph.1420",
      "volume": "59",
      "year": "2019"
    },
    {
      "DOI": "10.1016/j.phrs.2019.104590",
      "author": "S Koutsilieri",
      "doi-asserted-by": "publisher",
      "first-page": "104590",
      "journal-title": "Pharmacol Res",
      "key": "2282_CR31",
      "unstructured": "Koutsilieri S, Tzioufa F, Sismanoglou DC, Patrinos GP (2020) Unveiling the guidance heterogeneity for genome-informed drug treatment interventions among regulatory bodies and research consortia. Pharmacol Res 153:104590. https://doi.org/10.1016/j.phrs.2019.104590",
      "volume": "153",
      "year": "2020"
    },
    {
      "DOI": "10.1161/CIRCULATIONAHA.119.044770",
      "author": "MG Levin",
      "doi-asserted-by": "publisher",
      "first-page": "637",
      "journal-title": "Circulation",
      "key": "2282_CR32",
      "unstructured": "Levin MG, Rader DJ (2020) Polygenic risk scores and coronary artery disease: ready for prime time? Circulation 141:637–640. https://doi.org/10.1161/CIRCULATIONAHA.119.044770",
      "volume": "141",
      "year": "2020"
    },
    {
      "DOI": "10.1093/ehjcvp/pvz045",
      "author": "JP Lewis",
      "doi-asserted-by": "publisher",
      "first-page": "203",
      "journal-title": "Eur Heart J Cardiovasc Pharmacother",
      "key": "2282_CR33",
      "unstructured": "Lewis JP, Backman JD, Reny JL, Bergmeijer TO, Mitchell BD, Ritchie MD, Dery JP, Pakyz RE, Gong L, Ryan K, Kim EY, Aradi D, Fernandez-Cadenas I, Lee MTM, Whaley RM, Montaner J, Gensini GF, Cleator JH, Chang K, Holmvang L, Hochholzer W, Roden DM, Winter S, Altman RB, Alexopoulos D, Kim HS, Gawaz M, Bliden KP, Valgimigli M, Marcucci R, Campo G, Schaeffeler E, Dridi NP, Wen MS, Shin JG, Fontana P, Giusti B, Geisler T, Kubo M, Trenk D, Siller-Matula JM, Ten Berg JM, Gurbel PA, Schwab M, Klein TE, Shuldiner AR, Investigators I (2020) Pharmacogenomic polygenic response score predicts ischaemic events and cardiovascular mortality in clopidogrel-treated patients. Eur Heart J Cardiovasc Pharmacother 6:203–210. https://doi.org/10.1093/ehjcvp/pvz045",
      "volume": "6",
      "year": "2020"
    },
    {
      "DOI": "10.1161/CIRCULATIONAHA.119.043805",
      "author": "NA Marston",
      "doi-asserted-by": "publisher",
      "first-page": "616",
      "journal-title": "Circulation",
      "key": "2282_CR34",
      "unstructured": "Marston NA, Kamanu FK, Nordio F, Gurmu Y, Roselli C, Sever PS, Pedersen TR, Keech AC, Wang H, Lira Pineda A, Giugliano RP, Lubitz SA, Ellinor PT, Sabatine MS, Ruff CT (2020) Predicting benefit from evolocumab therapy in patients with atherosclerotic disease using a genetic risk score: results from the FOURIER trial. Circulation 141:616–623. https://doi.org/10.1161/CIRCULATIONAHA.119.043805",
      "volume": "141",
      "year": "2020"
    },
    {
      "DOI": "10.1002/cpt.2122",
      "author": "G McInnes",
      "doi-asserted-by": "publisher",
      "journal-title": "Clin Pharmacol Ther",
      "key": "2282_CR35",
      "unstructured": "McInnes G, Lavertu A, Sangkuhl K, Klein TE, Whirl-Carrillo M, Altman RB (2020) Pharmacogenetics at scale: an analysis of the UK biobank. Clin Pharmacol Ther. https://doi.org/10.1002/cpt.2122",
      "year": "2020"
    },
    {
      "DOI": "10.1016/S0140-6736(14)61730-X",
      "author": "JL Mega",
      "doi-asserted-by": "publisher",
      "first-page": "2264",
      "journal-title": "Lancet",
      "key": "2282_CR36",
      "unstructured": "Mega JL, Stitziel NO, Smith JG, Chasman DI, Caulfield M, Devlin JJ, Nordio F, Hyde C, Cannon CP, Sacks F, Poulter N, Sever P, Ridker PM, Braunwald E, Melander O, Kathiresan S, Sabatine MS (2015) Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials. Lancet 385:2264–2271. https://doi.org/10.1016/S0140-6736(14)61730-X",
      "volume": "385",
      "year": "2015"
    },
    {
      "key": "2282_CR37",
      "unstructured": "MoHW (2019) https://law.moj.gov.tw/Eng/LawClass/LawAll.aspx?PCode=L0020164. Accessed 8 Mar 2021"
    },
    {
      "key": "2282_CR38",
      "unstructured": "MoSAH (2012) https://finlex.fi/en/laki/kaannokset/2012/en20120688.pdf. Accessed 8 Mar 2021"
    },
    {
      "key": "2282_CR50",
      "unstructured": "MRCT-Center (2017) Return of Individual Results to Participants Recommendations Document. https://mrctcenter.org/wp-content/uploads/2017/12/2017-12-07-Return-of-Individual-Resullts-Recommendations-Document-V-1.2.pdf. Accessed 8 Mar 2021"
    },
    {
      "DOI": "10.1161/CIRCULATIONAHA.116.024436",
      "author": "P Natarajan",
      "doi-asserted-by": "publisher",
      "first-page": "2091",
      "journal-title": "Circulation",
      "key": "2282_CR39",
      "unstructured": "Natarajan P, Young R, Stitziel NO, Padmanabhan S, Baber U, Mehran R, Sartori S, Fuster V, Reilly DF, Butterworth A, Rader DJ, Ford I, Sattar N, Kathiresan S (2017) Polygenic risk score identifies subgroup with higher burden of atherosclerosis and greater relative benefit from statin therapy in the primary prevention setting. Circulation 135:2091–2101. https://doi.org/10.1161/CIRCULATIONAHA.116.024436",
      "volume": "135",
      "year": "2017"
    },
    {
      "DOI": "10.1038/ng.3314",
      "author": "MR Nelson",
      "doi-asserted-by": "publisher",
      "first-page": "856",
      "journal-title": "Nat Genet",
      "key": "2282_CR40",
      "unstructured": "Nelson MR, Tipney H, Painter JL, Shen J, Nicoletti P, Shen Y, Floratos A, Sham PC, Li MJ, Wang J, Cardon LR, Whittaker JC, Sanseau P (2015) The support of human genetic evidence for approved drug indications. Nat Genet 47:856–860. https://doi.org/10.1038/ng.3314",
      "volume": "47",
      "year": "2015"
    },
    {
      "DOI": "10.1038/nrg.2016.12",
      "author": "MR Nelson",
      "doi-asserted-by": "publisher",
      "first-page": "197",
      "journal-title": "Nat Rev Genet",
      "key": "2282_CR41",
      "unstructured": "Nelson MR, Johnson T, Warren L, Hughes AR, Chissoe SL, Xu CF, Waterworth DM (2016) The genetics of drug efficacy: opportunities and challenges. Nat Rev Genet 17:197–206. https://doi.org/10.1038/nrg.2016.12",
      "volume": "17",
      "year": "2016"
    },
    {
      "key": "2282_CR42",
      "unstructured": "NHC (2004) https://conselho.saude.gov.br/resolucoes/2004/Res340_en.pdf. Accessed 8 Mar 2021"
    },
    {
      "key": "2282_CR43",
      "unstructured": "NVK (2020). https://en.nvk.dk/rules-and-guidelines. Accessed 8 Mar 2021"
    },
    {
      "DOI": "10.1001/jama.2020.12443",
      "author": "NL Pereira",
      "doi-asserted-by": "publisher",
      "first-page": "761",
      "journal-title": "JAMA",
      "key": "2282_CR44",
      "unstructured": "Pereira NL, Farkouh ME, So D, Lennon R, Geller N, Mathew V, Bell M, Bae JH, Jeong MH, Chavez I, Gordon P, Abbott JD, Cagin C, Baudhuin L, Fu YP, Goodman SG, Hasan A, Iturriaga E, Lerman A, Sidhu M, Tanguay JF, Wang L, Weinshilboum R, Welsh R, Rosenberg Y, Bailey K, Rihal C (2020) Effect of genotype-guided oral P2Y12 inhibitor selection vs conventional clopidogrel therapy on ischemic outcomes after percutaneous coronary intervention: the TAILOR-PCI randomized clinical trial. JAMA 324:761–771. https://doi.org/10.1001/jama.2020.12443",
      "volume": "324",
      "year": "2020"
    },
    {
      "DOI": "10.1002/cpt.1004",
      "author": "EJ Phillips",
      "doi-asserted-by": "publisher",
      "first-page": "574",
      "journal-title": "Clin Pharmacol Ther",
      "key": "2282_CR45",
      "unstructured": "Phillips EJ, Sukasem C, Whirl-Carrillo M, Muller DJ, Dunnenberger HM, Chantratita W, Goldspiel B, Chen YT, Carleton BC, George AL Jr, Mushiroda T, Klein T, Gammal RS, Pirmohamed M (2018) Clinical pharmacogenetics implementation consortium guideline for HLA genotype and use of carbamazepine and oxcarbazepine: 2017 update. Clin Pharmacol Ther 103:574–581. https://doi.org/10.1002/cpt.1004",
      "volume": "103",
      "year": "2018"
    },
    {
      "DOI": "10.1038/538161a",
      "author": "AB Popejoy",
      "doi-asserted-by": "publisher",
      "first-page": "161",
      "journal-title": "Nature",
      "key": "2282_CR46",
      "unstructured": "Popejoy AB, Fullerton SM (2016) Genomics is failing on diversity. Nature 538:161–164. https://doi.org/10.1038/538161a",
      "volume": "538",
      "year": "2016"
    },
    {
      "DOI": "10.1111/bioe.12073",
      "author": "SK Prucka",
      "doi-asserted-by": "publisher",
      "first-page": "82",
      "journal-title": "Bioethics",
      "key": "2282_CR47",
      "unstructured": "Prucka SK, Arnold LJ, Brandt JE, Gilardi S, Harty LC, Hong F, Malia J, Pulford DJ (2015) An update to returning genetic research results to individuals: perspectives of the industry pharmacogenomics working group. Bioethics 29:82–90. https://doi.org/10.1111/bioe.12073",
      "volume": "29",
      "year": "2015"
    },
    {
      "key": "2282_CR48",
      "unstructured": "Regeringskansliet (2002) https://biobanksverige.se/wp-content/uploads/Biobanks-in-medical-care-act-2002-297.pdf. Accessed 8 Mar 2021"
    },
    {
      "DOI": "10.1002/cpt.1651",
      "author": "MV Relling",
      "doi-asserted-by": "publisher",
      "first-page": "171",
      "journal-title": "Clin Pharmacol Ther",
      "key": "2282_CR49",
      "unstructured": "Relling MV, Klein TE, Gammal RS, Whirl-Carrillo M, Hoffman JM, Caudle KE (2020) The clinical pharmacogenetics implementation consortium: 10 years later. Clin Pharmacol Ther 107:171–175. https://doi.org/10.1002/cpt.1651",
      "volume": "107",
      "year": "2020"
    },
    {
      "DOI": "10.1101/cshperspect.a033027",
      "author": "UI Schwarz",
      "doi-asserted-by": "publisher",
      "journal-title": "Cold Spring Harb Perspect Med",
      "key": "2282_CR51",
      "unstructured": "Schwarz UI, Gulilat M, Kim RB (2019) The role of next-generation sequencing in pharmacogenetics and pharmacogenomics. Cold Spring Harb Perspect Med. https://doi.org/10.1101/cshperspect.a033027",
      "year": "2019"
    },
    {
      "DOI": "10.1097/FPC.0b013e32834d4962",
      "author": "SA Scott",
      "doi-asserted-by": "publisher",
      "first-page": "159",
      "journal-title": "Pharmacogenet Genomics",
      "key": "2282_CR52",
      "unstructured": "Scott SA, Sangkuhl K, Shuldiner AR, Hulot JS, Thorn CF, Altman RB, Klein TE (2012) PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 19. Pharmacogenet Genomics 22:159–165. https://doi.org/10.1097/FPC.0b013e32834d4962",
      "volume": "22",
      "year": "2012"
    },
    {
      "DOI": "10.1002/cpt.1720",
      "author": "R Shekhani",
      "doi-asserted-by": "publisher",
      "first-page": "1240",
      "journal-title": "Clin Pharmacol Ther",
      "key": "2282_CR53",
      "unstructured": "Shekhani R, Steinacher L, Swen JJ, Ingelman-Sundberg M (2020) Evaluation of current regulation and guidelines of pharmacogenomic drug labels: opportunities for improvements. Clin Pharmacol Ther 107:1240–1255. https://doi.org/10.1002/cpt.1720",
      "volume": "107",
      "year": "2020"
    },
    {
      "DOI": "10.1128/mSphere.00232-20",
      "author": "J Shen",
      "doi-asserted-by": "publisher",
      "journal-title": "mSphere",
      "key": "2282_CR54",
      "unstructured": "Shen J, Mehrotra DV, Dorr MB, Zeng Z, Li J, Xu X, Nickle D, Holzinger ER, Chhibber A, Wilcox MH, Blanchard RL, Shaw PM (2020) Genetic association reveals protection against recurrence of clostridium difficile infection with bezlotoxumab treatment. mSphere. https://doi.org/10.1128/mSphere.00232-20",
      "year": "2020"
    },
    {
      "key": "2282_CR55",
      "unstructured": "Spain (2007) https://www.isciii.es/QueHacemos/Financiacion/solicitudes/Documents/SpanishLawonBiomedicalResearchEnglish.pdf. Accessed 8 Mar 2021"
    },
    {
      "DOI": "10.1101/2020.11.02.20222232",
      "author": "JD Szustakowski",
      "doi-asserted-by": "publisher",
      "journal-title": "medRxiv",
      "key": "2282_CR56",
      "unstructured": "Szustakowski JD, Balasubramanian S, Sasson A, Khalid S, Bronson PG, Kvikstad E, Wong E, Liu D, Davis JW, Haefliger C, Loomis AK, Mikkilineni R, Noh HJ, Wadhawan S, Bai X, Hawes A, Krasheninina O, Ulloa R, Lopez A, Smith EN, Waring J, Whelan CD, Tsai EA, Overton J, Salerno W, Jacob H, Szalma S, Runz H, Hinkle G, Nioi P, Petrovski S, Miller MR, Baras A, Mitnaul L, Reid JG (2020) Advancing human genetics research and drug discovery through exome sequencing of the UK biobank. medRxiv. https://doi.org/10.1101/2020.11.02.20222232",
      "year": "2020"
    },
    {
      "DOI": "10.1038/s41431-018-0311-3",
      "author": "A Thorogood",
      "doi-asserted-by": "publisher",
      "first-page": "535",
      "journal-title": "Eur J Hum Genet",
      "key": "2282_CR57",
      "unstructured": "Thorogood A, Dalpe G, Knoppers BM (2019) Return of individual genomic research results: are laws and policies keeping step? Eur J Hum Genet 27:535–546. https://doi.org/10.1038/s41431-018-0311-3",
      "volume": "27",
      "year": "2019"
    },
    {
      "DOI": "10.2217/pgs.15.141",
      "author": "L Tremaine",
      "doi-asserted-by": "publisher",
      "first-page": "2055",
      "journal-title": "Pharmacogenomics",
      "key": "2282_CR58",
      "unstructured": "Tremaine L, Brian W, DelMonte T, Francke S, Groenen P, Johnson K, Li L, Pearson K, Marshall JC (2015) The role of ADME pharmacogenomics in early clinical trials: perspective of the Industry Pharmacogenomics Working Group (I-PWG). Pharmacogenomics 16:2055–2067. https://doi.org/10.2217/pgs.15.141",
      "volume": "16",
      "year": "2015"
    },
    {
      "DOI": "10.1038/s41586-020-2853-0",
      "author": "CV Van Hout",
      "doi-asserted-by": "publisher",
      "first-page": "749",
      "journal-title": "Nature",
      "key": "2282_CR59",
      "unstructured": "Van Hout CV, Tachmazidou I, Backman JD, Hoffman JD, Liu D, Pandey AK, Gonzaga-Jauregui C, Khalid S, Ye B, Banerjee N, Li AH, O’Dushlaine C, Marcketta A, Staples J, Schurmann C, Hawes A, Maxwell E, Barnard L, Lopez A, Penn J, Habegger L, Blumenfeld AL, Bai X, O’Keeffe S, Yadav A, Praveen K, Jones M, Salerno WJ, Chung WK, Surakka I, Willer CJ, Hveem K, Leader JB, Carey DJ, Ledbetter DH, Geisinger-Regeneron Discov EHRC, Cardon L, Yancopoulos GD, Economides A, Coppola G, Shuldiner AR, Balasubramanian S, Cantor M, Regeneron Genetics C, Nelson MR, Whittaker J, Reid JG, Marchini J, Overton JD, Scott RA, Abecasis GR, Yerges-Armstrong L, Baras A (2020) Exome sequencing and characterization of 49,960 individuals in the UK Biobank. Nature 586:749–756. https://doi.org/10.1038/s41586-020-2853-0",
      "volume": "586",
      "year": "2020"
    },
    {
      "DOI": "10.1182/blood-2008-04-149070",
      "author": "M Wadelius",
      "doi-asserted-by": "publisher",
      "first-page": "784",
      "journal-title": "Blood",
      "key": "2282_CR60",
      "unstructured": "Wadelius M, Chen LY, Lindh JD, Eriksson N, Ghori MJ, Bumpstead S, Holm L, McGinnis R, Rane A, Deloukas P (2009) The largest prospective warfarin-treated cohort supports genetic forecasting. Blood 113:784–792. https://doi.org/10.1182/blood-2008-04-149070",
      "volume": "113",
      "year": "2009"
    },
    {
      "DOI": "10.1002/cpt.1098",
      "author": "SW Yee",
      "doi-asserted-by": "publisher",
      "first-page": "803",
      "journal-title": "Clin Pharmacol Ther",
      "key": "2282_CR61",
      "unstructured": "Yee SW, Brackman DJ, Ennis EA, Sugiyama Y, Kamdem LK, Blanchard R, Galetin A, Zhang L, Giacomini KM (2018) Influence of transporter polymorphisms on drug disposition and response: a perspective from the international transporter consortium. Clin Pharmacol Ther 104:803–817. https://doi.org/10.1002/cpt.1098",
      "volume": "104",
      "year": "2018"
    },
    {
      "DOI": "10.1038/s41436-019-0667-y",
      "author": "Y Zhu",
      "doi-asserted-by": "publisher",
      "first-page": "475",
      "journal-title": "Genet Med",
      "key": "2282_CR62",
      "unstructured": "Zhu Y, Swanson KM, Rojas RL, Wang Z, St Sauver JL, Visscher SL, Prokop LJ, Bielinski SJ, Wang L, Weinshilboum R, Borah BJ (2020) Systematic review of the evidence on the cost-effectiveness of pharmacogenomics-guided treatment for cardiovascular diseases. Genet Med 22:475–486. https://doi.org/10.1038/s41436-019-0667-y",
      "volume": "22",
      "year": "2020"
    }
  ],
  "reference-count": 62,
  "references-count": 62,
  "resource": {
    "primary": {
      "URL": "https://link.springer.com/10.1007/s00439-021-02282-3"
    }
  },
  "score": 0,
  "short-container-title": [
    "Hum Genet"
  ],
  "source": "Crossref",
  "title": [
    "Current challenges and opportunities for pharmacogenomics: perspective of the Industry Pharmacogenomics Working Group (I-PWG)"
  ],
  "type": "journal-article",
  "update-policy": "http://dx.doi.org/10.1007/springer_crossmark_policy",
  "volume": "141"
}